TY - JOUR
T1 - Interactive Remote Patient Monitoring Devices for Managing Chronic Health Conditions
T2 - Systematic Review and Meta-analysis
AU - TAILOR investigators
AU - Leo, Donato Giuseppe
AU - Buckley, Benjamin J.R.
AU - Chowdhury, Mahin
AU - Harrison, Stephanie L.
AU - Isanejad, Masoud
AU - Lip, Gregory Y.H.
AU - Wright, David J.
AU - Lane, Deirdre A.
N1 - Funding Information:
The authors would like to thank all the Telehealth and Artificial Intelligence for Older People (TAILOR) investigators: Dr Asan Akpan, Dr Girvan Burnside (University of Liverpool), Mr Robert Halhead, Mr Stephen Hope, Mr Peter Levene, Mr Geoff Hayllar (Docobo Ltd, Leatherhead, United Kingdom), Mr Peter Almond (Mersey Care National Health Service Trust), Ms Sarah Dyas (Clinical Research Network, North West Coast), and Ms Lindsay Sharples (Innovation Agency). The authors would also like to thank Dr Marie Held (University of Liverpool) for her help in translating some of the included papers from German to English. This project has received funding from the Liverpool Clinical Commissioning Group, Research Capability Funding (LCCG-RCF20-21-01).
Funding Information:
The authors would like to thank all the Telehealth and Artificial Intelligence for Older People (TAILOR) investigators: Dr Asan Akpan, Dr Girvan Burnside (University of Liverpool), Mr Robert Halhead, Mr Stephen Hope, Mr Peter Levene, Mr Geoff Hayllar (Docobo Ltd, Leatherhead, United Kingdom), Mr Peter Almond (Mersey Care National Health Service Trust), Ms Sarah Dyas (Clinical Research Network, North West Coast), and Ms Lindsay Sharples (Innovation Agency). The authors would also like to thank Dr Marie Held (University of Liverpool) for her help in translating some of the included papers from German to English. This project has received funding from the Liverpool Clinical Commissioning Group, Research Capability Funding (LCCG_RCF20-21_01).
Funding Information:
BJRB has received research funding from the Bristol Myers Squibb (BMS)-Pfizer Alliance. SLH has received an investigator-initiated grant from BMS. GYHL has been a consultant and speaker for the BMS-Pfizer Alliance, Boehringer Ingelheim, and Daiichi-Sankyo. No fees were received personally. DJW has been a consultant and speaker for Medtronic and Boston Scientific. DAL has received investigator-initiated educational grants from BMS; been a speaker for Boehringer Ingelheim, Bayer, and the BMS-Pfizer Alliance; and consulted for Boehringer Ingelheim, Bayer, and the BMS-Pfizer Alliance, all outside the submitted work.
Publisher Copyright:
© 2022 Donato Giuseppe Leo.
PY - 2022/11
Y1 - 2022/11
N2 - Background: Telemedicine is an expanding and feasible approach to improve medical care for patients with long-term conditions. However, there is a poor understanding of patients' acceptability of this technology and their rate of uptake. Objective: The aim of this study was to systematically review the current evidence on telemonitoring in the management of patients with long-term conditions and evaluate the patients' uptake and acceptability of this technology. Methods: MEDLINE, Scopus, and CENTRAL (the Cochrane Central Register of Controlled Trials) were searched from the date of inception to February 5, 2021, with no language restrictions. Studies were eligible for inclusion if they reported any of the following outcomes: intervention uptake and adherence; study retention; patient acceptability, satisfaction, and experience using the intervention; changes in physiological values; all-cause and cardiovascular-related hospitalization; all-cause and disease-specific mortality; patient-reported outcome measures; and quality of life. In total, 2 reviewers independently assessed the articles for eligibility. Results: A total of 96 studies were included, and 58 (60%) were pooled for the meta-analyses. Meta-analyses showed a reduction in mortality (risk ratio=0.71, 95% CI 0.56-0.89; P=.003; I2=0%) and improvements in blood pressure (mean difference [MD]=-3.85 mm Hg, 95% CI -7.03 to -0.68; P=.02; I2=100%) and glycated hemoglobin (MD=-0.33, 95% CI -0.57 to -0.09; P=.008; I2=99%) but no significant improvements in quality of life (MD=1.45, 95% CI -0.10 to 3; P=.07; I2=80%) and an increased risk of hospitalization (risk ratio=1.02, 95% CI 0.85-1.23; P=.81; I2=79%) with telemonitoring compared with usual care. A total of 12% (12/96) of the studies reported adherence outcomes, and 9% (9/96) reported on satisfaction and acceptance outcomes; however, heterogeneity in the assessment methods meant that a meta-analysis could not be performed. Conclusions: Telemonitoring is a valid alternative to usual care, reducing mortality and improving self-management of the disease, with patients reporting good satisfaction and adherence. Further studies are required to address some potential concerns regarding higher hospitalization rates and a lack of positive impact on patients' quality of life.
AB - Background: Telemedicine is an expanding and feasible approach to improve medical care for patients with long-term conditions. However, there is a poor understanding of patients' acceptability of this technology and their rate of uptake. Objective: The aim of this study was to systematically review the current evidence on telemonitoring in the management of patients with long-term conditions and evaluate the patients' uptake and acceptability of this technology. Methods: MEDLINE, Scopus, and CENTRAL (the Cochrane Central Register of Controlled Trials) were searched from the date of inception to February 5, 2021, with no language restrictions. Studies were eligible for inclusion if they reported any of the following outcomes: intervention uptake and adherence; study retention; patient acceptability, satisfaction, and experience using the intervention; changes in physiological values; all-cause and cardiovascular-related hospitalization; all-cause and disease-specific mortality; patient-reported outcome measures; and quality of life. In total, 2 reviewers independently assessed the articles for eligibility. Results: A total of 96 studies were included, and 58 (60%) were pooled for the meta-analyses. Meta-analyses showed a reduction in mortality (risk ratio=0.71, 95% CI 0.56-0.89; P=.003; I2=0%) and improvements in blood pressure (mean difference [MD]=-3.85 mm Hg, 95% CI -7.03 to -0.68; P=.02; I2=100%) and glycated hemoglobin (MD=-0.33, 95% CI -0.57 to -0.09; P=.008; I2=99%) but no significant improvements in quality of life (MD=1.45, 95% CI -0.10 to 3; P=.07; I2=80%) and an increased risk of hospitalization (risk ratio=1.02, 95% CI 0.85-1.23; P=.81; I2=79%) with telemonitoring compared with usual care. A total of 12% (12/96) of the studies reported adherence outcomes, and 9% (9/96) reported on satisfaction and acceptance outcomes; however, heterogeneity in the assessment methods meant that a meta-analysis could not be performed. Conclusions: Telemonitoring is a valid alternative to usual care, reducing mortality and improving self-management of the disease, with patients reporting good satisfaction and adherence. Further studies are required to address some potential concerns regarding higher hospitalization rates and a lack of positive impact on patients' quality of life.
KW - chronic condition
KW - eHealth
KW - meta-analysis
KW - self-monitoring
KW - systematic review
KW - telemedicine
KW - telemonitoring
UR - http://www.scopus.com/inward/record.url?scp=85141890050&partnerID=8YFLogxK
U2 - 10.2196/35508
DO - 10.2196/35508
M3 - Review article
C2 - 36326818
AN - SCOPUS:85141890050
SN - 1438-8871
VL - 24
JO - Journal of Medical Internet Research
JF - Journal of Medical Internet Research
IS - 11
M1 - e35508
ER -